Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for ������������������������������:kn39������������������������,������24������,������������������������,���������������������,��������������� returned no results
Showing 106 to 120 of 359 results for ������������������������������:know������������������������,������24������,������������������������,���������������������,���������������

  1. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

  2. Coexisting severe mental illness and substance misuse (QS188)

    This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.

  3. Risdiplam for treating spinal muscular atrophy (TA755)

    Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.

  4. Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)

    Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.

  5. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

  6. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.

  7. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

  8. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

  9. Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

    Evidence-based recommendations on gemtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over.

  10. Carfilzomib for previously treated multiple myeloma (TA657)

    Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.

  11. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

  12. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  13. Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

    Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.

  14. Air pollution: outdoor air quality and health (QS181)

    This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.

  15. Our principles

    An outline of the key principles that are universal to all of NICE's guidance and standards.